通过工程外基因组对突变p53和SNRPD2进行双重向,调节替代分离以抑制卵巢癌
Wei Zhao1,2,3, Qian Hao4,5, Yu Gan4,5
1Department of Gynecology, Xiangya Hospital, Central South University, Changsha, China.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
|January 21, 2026
概括
突变p53 (mtp53) 和SNRPD2通过改变RNA拼接驱动卵巢癌. 用工程外体对两者进行向,为卵巢癌治疗提供了一个新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 在RNA分离过程中.
背景情况:
- TP53基因突变与卵巢癌的进展和治疗耐药性有关.
- 突变p53 (mtp53) 在调节替代拼接中的作用及其治疗含义尚未完全理解.
研究的目的:
- 为了研究mtp53和卵巢癌中的替代拼接之间的相互作用.
- 确定卵巢癌的潜在治疗点和策略.
主要方法:
- 通过生物化学分析,确定SNRPD2是mtp53的结合伙伴.
- 评估了SNRPD2在卵巢癌细胞生长和迁移中的作用.
- 研究了mtp53-SNRPD2在拼接体组装和替代拼接中的合作机制.
- 开发了装载着针对mtp53和SNRPD2的siRNAs的工程外体,用于治疗.
主要成果:
- 卵巢癌中SNRPD2过度表达,与预后不佳相关,并促进瘤生长和迁移.
- mtp53和SNRPD2通过促进Sm/SMN复杂组装来规范替代拼接.
- 同时减少mtp53和SNRPD2改变了前mRNA的替代拼接,减少了瘤性OTUD3转录.
- 工程外基因组有效地抑制了瘤生长,并在体内增强了化疗敏感性.
结论:
- mtp53和SNRPD2协同调节替代拼接,推动卵巢癌的进展.
- 使用工程外体共同准mtp53和SNRPD2是一种有前途的卵巢癌治疗策略.
相关概念视频
Alternative RNA Splicing
24.7K
Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
24.7K
Alternative RNA Splicing
4.9K
4.9K
RNA Splicing
60.4K
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
60.4K
Targeted Cancer Therapies
8.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.7K
Overview of Exosomes
3.6K
Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
3.6K
Chromatin Structure and RNA Splicing
3.3K
3.3K


